<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00657644</url>
  </required_header>
  <id_info>
    <org_study_id>11182</org_study_id>
    <nct_id>NCT00657644</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction</brief_title>
  <official_title>Open-label Multi-centre Non Randomised Study of Efficacy and Safety of Vardenafil (BAY 38-9456; SB-782528) Administered in Flexible-dose Regimen in Males With Erectile Dysfunction of Broad Aetiology.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To find out more information on how effective and safe vardenafil is at treating impotence in&#xD;
      men living in Russia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">March 2004</completion_date>
  <primary_completion_date type="Actual">March 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Erectile Function (EF) domain score</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Erectile Function (EF) domain score</measure>
    <time_frame>Week 4, 8 and 12 Last Observation Carried Forward (LOCF)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of Erectile Function domain score</measure>
    <time_frame>Week 4, 8 and 12 Last Observation Carried Forward (LOCF)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IIEF domain scores</measure>
    <time_frame>Week 4, 8, 12 and 12 Last Observation Carried Forward (LOCF)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Diary Questions</measure>
    <time_frame>Week 4, 8, 12 and 12 Last Observation Carried Forward (LOCF)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment Question (GAQ)</measure>
    <time_frame>Week 4, 8, 12 and 12 Last Observation Carried Forward (LOCF)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Premature termination, adverse events, laboratory abnormalities and concomitant medication usage</measure>
    <time_frame>Week 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurements and changes from baseline in vital signs, ECG cardiac cycle measurements and ECG heart rate</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology, Clinical Chemistry, Urinalysis</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levitra (Vardenafil, BAY38-9456)</intervention_name>
    <description>4 weeks treatment with 10 mg vardenafil followed by a flexible titration phase for 8 weeks</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males with ED according to the NIH definition (the inability to achieve or maintain&#xD;
             penile erection sufficient for satisfactory sexual performance) for at least 3 months.&#xD;
&#xD;
          -  Heterosexual relationship&#xD;
&#xD;
          -  Age range: 18 years and older&#xD;
&#xD;
          -  Documented written Informed Consent&#xD;
&#xD;
          -  The subject must make at least four attempts at sexual intercourse (according to the&#xD;
             question in the subject diary &quot;Was sexual activity initiated with the intention of&#xD;
             intercourse?&quot;) on four separate days during the untreated baseline period. At least&#xD;
             50% of attempts during this period must be unsuccessful, according to the following&#xD;
             questions from the subject diary [at least one question should be answered &quot;No&quot;] &quot;Were&#xD;
             you able to achieve at least partial erection (some enlargement of the penis)?&quot;, &quot;Were&#xD;
             you able to insert your penis in your partner's vagina?&quot; and &quot;Did your erection last&#xD;
             long enough for you to have successful intercourse?&quot;.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any unstable medical, psychiatric, or substance abuse disorder that in the opinion of&#xD;
             the Investigator is likely to affect the subject's ability to complete the study or&#xD;
             precludes the subject's participation in the study&#xD;
&#xD;
          -  Presence of penile anatomical abnormalities (e.g. penile fibrosis or Peyronie's&#xD;
             disease) that in the opinion of the Investigator would significantly impair erectile&#xD;
             function&#xD;
&#xD;
          -  Primary hypoactive sexual desire&#xD;
&#xD;
          -  Spinal cord injury&#xD;
&#xD;
          -  History of surgical prostatectomy (excluding TURP).&#xD;
&#xD;
          -  Retinitis pigmentosa&#xD;
&#xD;
          -  History of positive test for Hepatitis B surface antigen (HBsAg) or Hepatitis C.&#xD;
&#xD;
          -  History of positive test for HIV.9. Severe chronic or acute liver disease, history of&#xD;
             moderate or severe hepatic impairment.&#xD;
&#xD;
          -  Clinically significant chronic hematological disease, which may lead to priapism such&#xD;
             as sickle cell anemia and leukemia.&#xD;
&#xD;
          -  Bleeding disorder.&#xD;
&#xD;
          -  Significant active peptic ulceration.&#xD;
&#xD;
          -  Unstable angina pectoris&#xD;
&#xD;
          -  History of myocardial infarction, stroke or life-threatening arrhythmia within the&#xD;
             prior 6 months&#xD;
&#xD;
          -  Uncontrolled atrial fibrillation/flutter at screening (ventricular response rate &gt; 100&#xD;
             bpm).&#xD;
&#xD;
          -  Resting hypotension (a resting systolic blood pressure of &lt; 90 mm Hg) or hypertension&#xD;
             (a resting systolic blood pressure &gt; 170 mm Hg or a resting diastolic blood pressure &gt;&#xD;
             110 mm Hg)&#xD;
&#xD;
          -  NYHA Class III and IV heart failure&#xD;
&#xD;
          -  Symptomatic postural hypotension within 6 months of visit 1.&#xD;
&#xD;
          -  History of malignancy within the past 5 years (other than squamous or basal cell skin&#xD;
             cancer).&#xD;
&#xD;
        Concomitant Medication:&#xD;
&#xD;
          -  Subjects who are taking nitrates or nitric oxide donors.&#xD;
&#xD;
          -  Subjects who are taking anti-androgens&#xD;
&#xD;
          -  Subjects who are taking androgens.&#xD;
&#xD;
          -  Subjects who take anticoagulants, except for antiplatelet agents.&#xD;
&#xD;
          -  Subjects who have received any investigational drug (including placebo) within 30 days&#xD;
             of visit 1.6. Use of any treatment for ED within the 7 days of visit 1 or during the&#xD;
             study, including oral medications, vacuum devices, constrictive devices, injections or&#xD;
             urethral suppositories.&#xD;
&#xD;
          -  Subjects who are taking the following potent inhibitors of cytochrome P- 450 3A4: HIV&#xD;
             protease inhibitors such as ritonavir or indinavir, the anti-mycotic agents&#xD;
             itraconazole and ketoconazole (topical forms are allowed) or erythromycin.&#xD;
&#xD;
          -  Subjects who are taking alpha-blockers.&#xD;
&#xD;
        Abnormal Laboratory Values:&#xD;
&#xD;
          -  Subjects who have a serum total testosterone level greater than 25% below the lower&#xD;
             limit of normal according to the range of the testing laboratory&#xD;
&#xD;
          -  Subjects with a serum creatinine &gt;3.0 mg/dl&#xD;
&#xD;
          -  Elevation of AST and/or ALT &gt;3X the ULN.&#xD;
&#xD;
          -  Diabetic subjects with an HbA1c &gt;12%.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>105425</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>117837</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>123367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>125101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>127206</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <zip>198013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>April 8, 2008</study_first_submitted>
  <study_first_submitted_qc>April 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2008</study_first_posted>
  <last_update_submitted>December 23, 2014</last_update_submitted>
  <last_update_submitted_qc>December 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erectile Dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vardenafil Dihydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

